Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients

Journal of Human Virology

Volumn 1, Issue 4, 1998, Pages 293-298

  Gringeri, A ^a,g   Santagostino, E ^a   Muca Perja M ^a   Mannucci, P M ^a   Zagury, J F ^b   Bizzini, B ^b   Lachgar, A ^b   Carcagno, M ^c   Rappaport, J ^d   Criscuolo, M ^c   Blattner, W ^e   Burny, A ^f   Gallo, R C ^e   Zagury, D ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SORBONNE UNIVERSITÉ   (France)

^c Biosidus SA   (Argentina)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e INSTITUTE OF HUMAN VIROLOGY   (United States)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g Hemophilia and Thrombosis Center   (Italy)

Author keywords

AIDS; Immunization; Immunotherapy; Tat protein

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNOLOGY; MALE; PHASE 1 CLINICAL TRIAL; PILOT STUDY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; MALE; PILOT PROJECTS;

EID: 0032057287     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Arya SK, Guo C, Josephs SF, Wong-Staal F. Transactivator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985;229:69-73.
2. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986;322:470-474.
3. Laspia MF, Rice AP, Mathews MD. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989;59:283-292.
4. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-86.
5. Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991;10:1733-1739.
6. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-287.
7. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transcription. J Virol 1993;67:277-287.
8. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 1995;375:497-500.
9. Barillari G, Buonaguro L, Fiorelli V, et al. Effects of cytokines from activated immune cells on vasuclar cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992; 149:3727-3734.
10. Mitola S, Sozzani S, Luini W, et al. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 1997;90:1365-1372.
11. Maroder M, Scarpa S, Screpanit I, et al. Human immunodeficiency virus type 1 tat protein modulates fibronectin expression in thymic epithelial cells and impairs in vitro thymocyte development. Cell Immunol 1996;168:49-58.
12. Viscidi RP, Mayur K, Lederman HM, Frankel AD. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;246:1606-1608.
13. Chirmule N, Than S, Khan SA, Pahwa S. Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J Virol 1995;69:492-498.
14. Zagury JF, Chams V, Lachgar A, et al. Model of AIDS immunopathogenesis based on the HIV-1 gp 120 and Tat-induced dysregulation of uninfected immune cells. Cell Pharmacol AIDS Sci 1996;3:281-286.
15. Gougeon ML, Montagnier L. Apoptosis in AIDS. Science 1993;260:1269-1270.
16. Pantaleo G, Fauci AS. Tracking HIV-1 during disease progression. Curr Opin Immunol 1994;6:600-604.
17. Amiesen JC. Programmed cell death and AIDS: from hypothesis to experiment. Immunol Today 1992;13:388-391.
18. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995;268:429-431.
19. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Greenwald DR, Herzenberg LA, Herzenberg LA. HIV-1 type 1 Tat protein enhances activation but not Fas (CD95) induced peripheral blood T cell apoptosis in healthy individuals. Int Immunol 1997;9:835-841.
20. McCloskey TW, Ott M, Tribble E, et al. Dual role of HIV-1 Tat in regulation of apoptosis in T cells. J Immunol 1997; 158:1014-1019.
21. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, Pardee AB. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci U S A 1997;94:8116-8120
22. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371: 674-680.
23. Picard O, Achour A, Bernard J, et al. A 2-year follow-up of an anti-HIV-1 immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. J AIDS 1992;5:539-546.
24. Hendel H, Cho YY, Gauthier N, Rappaport J, Schächter F, Zagury JF. Contribution of cohort studies in understanding HIV-1 pathogenesis: introduction of the GRIV cohort and preliminary results. BioMed Pharmacol 1996;50:480-487.
25. Rappaport J, Cho Y-Y, Hendel H, Schwartz E, Schächter F, Zagury J-F. 32 bp CCR5 gene deletion and resistance to fast progression among HIV-1 infected heterozygotes. Lancet 1997;349:922-923.
26. Zagury JF, Lachgar A, Le Buanec H, et al. Antibodies to the HIV-1 Tat protein correlate with non-progression to AIDS: a rationale for the use of a Tat toxoid as a therapeutic HIV-1 vaccine. J Hum Virol 1998;1:282-292.
27. Lolli S, Capitani S, La Placa M. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:408-416.
28. Krone WJ, Debouck C, Epstein LG, Heutink P, Meloen R, Goudsmit J. Natural antibodies to HIV-1-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988;26: 261-270.
29. Reiss P, de Wolf F, Kuiken CL, et al. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr 1991;4:165-172.
30. Zagury D, Lachgar A, Chams V, et al. IFN-α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A 1998;95:3851-3856.
31. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
32. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
33. Zagury D. A naturally unbalanced combat. Nat Med 1997; 3:156-157.